Women in midlife face a difficult trade-off. Many in their 40s to 60s face a high risk of breast cancer, especially during the transition into menopause.

Our conclusions The results of our analysis suggest that there is no superior drug combination for prevention of CINV for people receiving HEC or MEC. However, results suggest that the choice of drugs ...